Fenebrutinib met primary goals in two late-stage trials for the treatment of two different forms of multiple sclerosis.

Please provide your email address to receive an email when new articles are posted on . Patients with MS had lower corneal nerve fiber density, corneal nerve branch density and corneal nerve fiber ...

Differences in the complexity of the EEG signal (yellow and red colors) in a specific brain area between the group with advanced multiple sclerosis and the control group, and multifractal spectra ...

Roche Holding AG said a multiple sclerosis drug showed it could work for most forms of the disease in two late-stage trials, ...

The results from more than one-third of late-stage clinical trials that tested multiple sclerosis drugs were never published in peer-reviewed journals — and studies with negative or inconclusive ...

The drug appears effective against both “relapsing” and “primary progressive” forms of the disease, though some analysts ...

Criteria used by neurologists to assess for multiple sclerosis (MS) in adults may fail to identify the illness in children with imaging suspicious for the disease, an oversight that could delay ...

FRANKFURT, April 30 (Reuters) - Merck KGaA has started a mid-stage trial to evaluate the safety and efficacy of atacicept in patients with relapsing multiple sclerosis, the German drugs and chemicals ...

Roche (OTCQX:RHHBY) shares closed ~4% higher in Europe on Monday as the maker of Ocrevus multiple sclerosis therapy announced ...

This transcript has been edited for clarity. Joseph R. Berger, MD: Hi. I'm Dr Joseph Berger, and I'm joined for this Care Cues conversation with my patient, Michelle Biloon, who has had multiple ...

Roche's late-stage trial of fenebrutinib, a multiple sclerosis drug candidate, met its primary goal. The trial demonstrated a significant reduction in annualized relapse rates compared to ...

FSD Pharma (NASDAQ:HUGE) said it submitted a clinical trial application (CTA) seeking to start a phase 1 trial of Lucid-MS to treat multiple sclerosis (MS). Lucid-MS is a first-in-class ...